Contribution of Somatic Ras/Raf/Mitogen-Activated Protein Kinase Variants in the Hippocampus in Drug-Resistant Mesial Temporal Lobe Epilepsy
Creators: name: Lee, Nadine
name: Lee, Eunjung Alice
name: Stronge, Edward
name: Bizzotto, Sara
name: Chen, Ming Hui
name: Phillips, H. Westley
name: Lokan, Julie
name: Zhu, Guangya
name: Berkovic, Samuel F.
name: Kahle, Kristopher T.
name: Gunel, Murat
name: Kong, Wenna
name: Witkowski, Tom
name: Poduri, Annapurna
name: Robert, Stephanie M.
name: Heinzen, Erin L.
name: Adikari, Thiuni N.
name: Damisah, Eyiyemisi C.
name: Ye, Zimeng
name: Chahine, Yasmine
name: Nelson-Williams, Carol
name: Richardson, R. Mark
name: Yang, Edward
name: Huang, August Yue
name: Walsh, Christopher A.
name: Scheffer, Ingrid E.
name: DeLanerolle, Nihal
name: Kiziltug, Emre
name: Lai, Dulcie
name: Chhouk, Brian H.
name: Zhu, Jidong
name: Khoshkhoo, Sattar
name: Erson-Omay, E. Zeynep
name: Bl¼mcke, Ingmar
name: Spencer, Dennis D.
name: Wang, Yilan
name: Haider, Shozeb
name: Lifton, Richard P.
name: Hildebrand, Michael S.
name: Huttner, Anita
name: Alexandrescu, Sanda
Publisher: name: American Medical Association (AMA)
Year: 2023

description: Importance: Mesial temporal lobe epilepsy (MTLE) is the most common focal epilepsy subtype and is often refractory to antiseizure medications. While most patients with MTLE do not have pathogenic germline genetic variants, the contribution of postzygotic (ie, somatic) variants in the brain is unknown. Objective: To test the association between pathogenic somatic variants in the hippocampus and MTLE. Design, Setting, and Participants: This case-control genetic association study analyzed the DNA derived from hippocampal tissue of neurosurgically treated patients with MTLE and age-matched and sex-matched neurotypical controls. Participants treated at level 4 epilepsy centers were enrolled from 1988 through 2019, and clinical data were collected retrospectively. Whole-exome and gene-panel sequencing (each genomic region sequenced more than 500 times on average) were used to identify candidate pathogenic somatic variants. A subset of novel variants was functionally evaluated using cellular and molecular assays. Patients with nonlesional and lesional (mesial temporal sclerosis, focal cortical dysplasia, and low-grade epilepsy-associated tumors) drug-resistant MTLE who underwent anterior medial temporal lobectomy were eligible. All patients with available frozen tissue and appropriate consents were included. Control brain tissue was obtained from neurotypical donors at brain banks. Data were analyzed from June 2020 to August 2022. Exposures: Drug-resistant MTLE. Main Outcomes and Measures: Presence and abundance of pathogenic somatic variants in the hippocampus vs the unaffected temporal neocortex. Results: Of 105 included patients with MTLE, 53 (50.5%) were female, and the median (IQR) age was 32 (26-44) years; of 30 neurotypical controls, 11 (36.7%) were female, and the median (IQR) age was 37 (18-53) years. Eleven pathogenic somatic variants enriched in the hippocampus relative to the unaffected temporal neocortex (median [IQR] variant allele frequency, 1.92 [1.5-2.7] vs 0.3 [0-0.9]; P=.01) were detected in patients with MTLE but not in controls. Ten of these variants were in PTPN11, SOS1, KRAS, BRAF, and NF1, all predicted to constitutively activate Ras/Raf/mitogen-activated protein kinase (MAPK) signaling. Immunohistochemical studies of variant-positive hippocampal tissue demonstrated increased Erk1/2 phosphorylation, indicative of Ras/Raf/MAPK activation, predominantly in glial cells. Molecular assays showed abnormal liquid-liquid phase separation for the PTPN11 variants as a possible dominant gain-of-function mechanism. Conclusions and Relevance: Hippocampal somatic variants, particularly those activating Ras/Raf/MAPK signaling, may contribute to the pathogenesis of sporadic, drug-resistant MTLE. These findings may provide a novel genetic mechanism and highlight new therapeutic targets for this common indication for epilepsy surgery.